Subscribe

Your FREE subscription will give you access to articles, research reports, Biopharma CEO Confidence quarterly reports and much more!

Investment Firm Insights Gain Value from Our Up-to-Date Knowledge

Kineticos serves the strategy consulting needs of venture capital and private equity firms by working to maintain an intimate understanding of the most current life science industry topics and trends. Browse below for case studies, white papers, and articles pertaining to investment firms and the life science industry.

Click the Tabs Below for Investment Firm Case Studies, White Papers & Articles, and Blog


Case Studies
Articles
Blog
  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the

     

    Read this Case Study

  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. 

     

    Read this Case Study

  • Commercial Assessment

    Situation: A mid-sized biotech company evaluating their Phase II Metabolic asset requested that Kineticos provide a commercial and financial assessment

     

    Read this Case Study

  • Business Development and Licensing

    Situation: A publicly traded pharmaceutical company seeking a strategic partner for their IND-ready asset was in need of support with

     

    Read this Case Study

  • Pricing Strategy

    Situation: A global central laboratory services company was considering implementing a price increase across their lab services and requested Kineticos

     

    Read this Case Study

  • Medical Affairs Global Readiness

    Situation: As a NASDAQ traded oncology biotechnology company was preparing to expand globally, they requested Kineticos conduct a gap assessment

     

    Read this Case Study

  • A Look Inside the Diagnostics Market

    The life science ecosystem is a complex organism being influenced by patients, providers, payers, and regulators in the precision medicine,

     

    Read this Article

  • Overall Confidence in the Biopharmaceutical Industry is Strong Heading into Q4 2018

    The life science industry is an evolving ecosystem and defined by the network of interactions between biopharmaceutical companies, services firms,

     

    Read this Article

  • A Primer on Oncology Diagnostics

    The trend towards personalized medicine in the oncology space has been rapidly gaining traction with the advent of genetic analysis

     

    Read this Article

  • Leveraging the Virtual Pharma Model

    Written by Mark Osterman, Senior Vice President, Kineticos My colleague, Dr. Soo Kim, recently wrote a piece about the evolution

     

    Read this Article

  • On the Importance of Primary Market Research

    Written by Myung Soo Kim, PhD, Research Analyst, Kineticos Pharmaceutical companies are frequently challenged with determining the optimal clinical development

     

    Read this Article

  • Continued Companion Diagnostics Growth

    Written by Bill Finger, Executive Vice President & Managing Director, Kineticos Since I last touched on how popular the companion

     

    Read this Article

  • How Metrics Can Help Identify and Solve Operational Challenges

    Article Preview As the sophistication of operational practices across life sciences increases; unfortunately, so do the difficulty and complexity of

     

    Read this Blog Post

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as

     

    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

     

    Read this Blog Post

  • Driving Revenue and EBIDTA at CROs through Customer Loyalty

    Article Preview Determining customer satisfaction and loyalty is a difficult endeavor for most businesses. Traditional voice of customer surveys are

     

    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent

     

    Read this Blog Post

  • Next Generation Sequencing: Using Technology to Develop Mutually-Beneficial Partnerships

    Article Preview Arup Laboratories announced it will begin offering next-generation sequencing (NGS) based high resolution Human Leukocyte Antigen (HLA) genotyping

     

    Read this Blog Post


Contact Us Today to Discover How We Can Elevate Your Business Our Strategy Consulting Services Are Designed to Enhance Your Value

Contact Us Today
Top